 | • レポートコード：MRC2-11QY03228 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はバイオジェネリック医薬品のグローバル市場について調査・分析したレポートです。種類別（インスリン、成長ホルモン、モノクローナル抗体、その他）市場規模、用途別（病院、診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別バイオジェネリック医薬品の競争状況、市場シェア ・世界のバイオジェネリック医薬品市場：種類別市場規模 2015年-2020年（インスリン、成長ホルモン、モノクローナル抗体、その他） ・世界のバイオジェネリック医薬品市場：種類別市場規模予測 2021年-2026年（インスリン、成長ホルモン、モノクローナル抗体、その他） ・世界のバイオジェネリック医薬品市場：用途別市場規模 2015年-2020年（病院、診療所、研究センター） ・世界のバイオジェネリック医薬品市場：用途別市場規模予測 2021年-2026年（病院、診療所、研究センター） ・北米のバイオジェネリック医薬品市場分析：米国、カナダ ・ヨーロッパのバイオジェネリック医薬品市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのバイオジェネリック医薬品市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のバイオジェネリック医薬品市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのバイオジェネリック医薬品市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Sandoz International、Teva pharmaceutical industries、Mylan、3SBio、Shanghai Fosun Pharmaceutical、Tonghua Dongbao Pharmaceutical、Biocon、Reliance life sciences、Probiomed、Biosidus、AMEGA Biotech、Celltrion、LG life Science、Dong-A Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
Biogeneric drugs market is expected to increase in forecast period due to increased treatment options, value added services to care patient and healthcare community. Due to drugs introduces competition, increasing affordability of biologics which delivers saving for healthcare systems are the same factors which increase biogeneric drugs market. Introduction of affordable, high-quality biogenerics drugs improves access to life changing medicine for patients worldwide. Opportunities for generic drug products is huge but there are regulations that must be adhered to when strategizing the best ways to maximize a company’s return. Government regulation may be adhere the growth of drug development investment or planning an entry into a market with a new biogeneric products.
Market Analysis and Insights: Global Biogeneric Drugs Market
The global Biogeneric Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Biogeneric Drugs Scope and Market Size
Biogeneric Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biogeneric Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Biogeneric Drugs market is segmented into
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Segment by Application, the Biogeneric Drugs market is segmented into
Hospital
Clinics
Research Centers
Regional and Country-level Analysis
The Biogeneric Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Biogeneric Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Biogeneric Drugs Market Share Analysis
Biogeneric Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Biogeneric Drugs business, the date to enter into the Biogeneric Drugs market, Biogeneric Drugs product introduction, recent developments, etc.
The major vendors covered:
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical
1 Study Coverage
1.1 Biogeneric Drugs Product Introduction
1.2 Market Segments
1.3 Key Biogeneric Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Biogeneric Drugs Market Size Growth Rate by Type
1.4.2 Insulins
1.4.3 Growth Hormones
1.4.4 Monoclonal Antibodies
1.4.5 Others
1.5 Market by Application
1.5.1 Global Biogeneric Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Research Centers
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Biogeneric Drugs Market Size, Estimates and Forecasts
2.1.1 Global Biogeneric Drugs Revenue 2015-2026
2.1.2 Global Biogeneric Drugs Sales 2015-2026
2.2 Global Biogeneric Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Biogeneric Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Biogeneric Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Biogeneric Drugs Competitor Landscape by Players
3.1 Biogeneric Drugs Sales by Manufacturers
3.1.1 Biogeneric Drugs Sales by Manufacturers (2015-2020)
3.1.2 Biogeneric Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Biogeneric Drugs Revenue by Manufacturers
3.2.1 Biogeneric Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Biogeneric Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Biogeneric Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Biogeneric Drugs Revenue in 2019
3.2.5 Global Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Biogeneric Drugs Price by Manufacturers
3.4 Biogeneric Drugs Manufacturing Base Distribution, Product Types
3.4.1 Biogeneric Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Biogeneric Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Biogeneric Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Biogeneric Drugs Market Size by Type (2015-2020)
4.1.1 Global Biogeneric Drugs Sales by Type (2015-2020)
4.1.2 Global Biogeneric Drugs Revenue by Type (2015-2020)
4.1.3 Biogeneric Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Biogeneric Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Biogeneric Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Biogeneric Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Biogeneric Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Biogeneric Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Biogeneric Drugs Market Size by Application (2015-2020)
5.1.1 Global Biogeneric Drugs Sales by Application (2015-2020)
5.1.2 Global Biogeneric Drugs Revenue by Application (2015-2020)
5.1.3 Biogeneric Drugs Price by Application (2015-2020)
5.2 Biogeneric Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Biogeneric Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Biogeneric Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Biogeneric Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Biogeneric Drugs by Country
6.1.1 North America Biogeneric Drugs Sales by Country
6.1.2 North America Biogeneric Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Biogeneric Drugs Market Facts & Figures by Type
6.3 North America Biogeneric Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Biogeneric Drugs by Country
7.1.1 Europe Biogeneric Drugs Sales by Country
7.1.2 Europe Biogeneric Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Biogeneric Drugs Market Facts & Figures by Type
7.3 Europe Biogeneric Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Biogeneric Drugs by Region
8.1.1 Asia Pacific Biogeneric Drugs Sales by Region
8.1.2 Asia Pacific Biogeneric Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Biogeneric Drugs Market Facts & Figures by Type
8.3 Asia Pacific Biogeneric Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Biogeneric Drugs by Country
9.1.1 Latin America Biogeneric Drugs Sales by Country
9.1.2 Latin America Biogeneric Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Biogeneric Drugs Market Facts & Figures by Type
9.3 Central & South America Biogeneric Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Biogeneric Drugs by Country
10.1.1 Middle East and Africa Biogeneric Drugs Sales by Country
10.1.2 Middle East and Africa Biogeneric Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Biogeneric Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Biogeneric Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Sandoz International
11.1.1 Sandoz International Corporation Information
11.1.2 Sandoz International Description and Business Overview
11.1.3 Sandoz International Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Sandoz International Biogeneric Drugs Products Offered
11.1.5 Sandoz International Related Developments
11.2 Teva pharmaceutical industries
11.2.1 Teva pharmaceutical industries Corporation Information
11.2.2 Teva pharmaceutical industries Description and Business Overview
11.2.3 Teva pharmaceutical industries Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Teva pharmaceutical industries Biogeneric Drugs Products Offered
11.2.5 Teva pharmaceutical industries Related Developments
11.3 Mylan
11.3.1 Mylan Corporation Information
11.3.2 Mylan Description and Business Overview
11.3.3 Mylan Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Mylan Biogeneric Drugs Products Offered
11.3.5 Mylan Related Developments
11.4 3SBio
11.4.1 3SBio Corporation Information
11.4.2 3SBio Description and Business Overview
11.4.3 3SBio Sales, Revenue and Gross Margin (2015-2020)
11.4.4 3SBio Biogeneric Drugs Products Offered
11.4.5 3SBio Related Developments
11.5 Shanghai Fosun Pharmaceutical
11.5.1 Shanghai Fosun Pharmaceutical Corporation Information
11.5.2 Shanghai Fosun Pharmaceutical Description and Business Overview
11.5.3 Shanghai Fosun Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Shanghai Fosun Pharmaceutical Biogeneric Drugs Products Offered
11.5.5 Shanghai Fosun Pharmaceutical Related Developments
11.6 Tonghua Dongbao Pharmaceutical
11.6.1 Tonghua Dongbao Pharmaceutical Corporation Information
11.6.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
11.6.3 Tonghua Dongbao Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Products Offered
11.6.5 Tonghua Dongbao Pharmaceutical Related Developments
11.7 Biocon
11.7.1 Biocon Corporation Information
11.7.2 Biocon Description and Business Overview
11.7.3 Biocon Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Biocon Biogeneric Drugs Products Offered
11.7.5 Biocon Related Developments
11.8 Reliance life sciences
11.8.1 Reliance life sciences Corporation Information
11.8.2 Reliance life sciences Description and Business Overview
11.8.3 Reliance life sciences Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Reliance life sciences Biogeneric Drugs Products Offered
11.8.5 Reliance life sciences Related Developments
11.9 Probiomed
11.9.1 Probiomed Corporation Information
11.9.2 Probiomed Description and Business Overview
11.9.3 Probiomed Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Probiomed Biogeneric Drugs Products Offered
11.9.5 Probiomed Related Developments
11.10 Biosidus
11.10.1 Biosidus Corporation Information
11.10.2 Biosidus Description and Business Overview
11.10.3 Biosidus Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Biosidus Biogeneric Drugs Products Offered
11.10.5 Biosidus Related Developments
11.1 Sandoz International
11.1.1 Sandoz International Corporation Information
11.1.2 Sandoz International Description and Business Overview
11.1.3 Sandoz International Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Sandoz International Biogeneric Drugs Products Offered
11.1.5 Sandoz International Related Developments
11.12 Celltrion
11.12.1 Celltrion Corporation Information
11.12.2 Celltrion Description and Business Overview
11.12.3 Celltrion Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Celltrion Products Offered
11.12.5 Celltrion Related Developments
11.13 LG life Science
11.13.1 LG life Science Corporation Information
11.13.2 LG life Science Description and Business Overview
11.13.3 LG life Science Sales, Revenue and Gross Margin (2015-2020)
11.13.4 LG life Science Products Offered
11.13.5 LG life Science Related Developments
11.14 Dong-A Pharmaceutical
11.14.1 Dong-A Pharmaceutical Corporation Information
11.14.2 Dong-A Pharmaceutical Description and Business Overview
11.14.3 Dong-A Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Dong-A Pharmaceutical Products Offered
11.14.5 Dong-A Pharmaceutical Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Biogeneric Drugs Market Estimates and Projections by Region
12.1.1 Global Biogeneric Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Biogeneric Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Biogeneric Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Biogeneric Drugs Sales Forecast (2021-2026)
12.2.2 North America: Biogeneric Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Biogeneric Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Biogeneric Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Biogeneric Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Biogeneric Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Biogeneric Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Biogeneric Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Biogeneric Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Biogeneric Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Biogeneric Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Biogeneric Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Biogeneric Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Biogeneric Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Biogeneric Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Biogeneric Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Biogeneric Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Biogeneric Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Biogeneric Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Biogeneric Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Biogeneric Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Biogeneric Drugs Market Segments
Table 2. Ranking of Global Top Biogeneric Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Biogeneric Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Insulins
Table 5. Major Manufacturers of Growth Hormones
Table 6. Major Manufacturers of Monoclonal Antibodies
Table 7. Major Manufacturers of Others
Table 8. Global Biogeneric Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 9. Global Biogeneric Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 10. Global Biogeneric Drugs Sales by Regions 2015-2020 (K MT)
Table 11. Global Biogeneric Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Biogeneric Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Biogeneric Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 14. Global Biogeneric Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Biogeneric Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Biogeneric Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biogeneric Drugs as of 2019)
Table 17. Biogeneric Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Biogeneric Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Biogeneric Drugs Price (2015-2020) (USD/MT)
Table 20. Biogeneric Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Biogeneric Drugs Product Type
Table 22. Date of International Manufacturers Enter into Biogeneric Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Biogeneric Drugs Sales by Type (2015-2020) (K MT)
Table 25. Global Biogeneric Drugs Sales Share by Type (2015-2020)
Table 26. Global Biogeneric Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Biogeneric Drugs Revenue Share by Type (2015-2020)
Table 28. Biogeneric Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 29. Global Biogeneric Drugs Sales by Application (2015-2020) (K MT)
Table 30. Global Biogeneric Drugs Sales Share by Application (2015-2020)
Table 31. North America Biogeneric Drugs Sales by Country (2015-2020) (K MT)
Table 32. North America Biogeneric Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Biogeneric Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Biogeneric Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Biogeneric Drugs Sales by Type (2015-2020) (K MT)
Table 36. North America Biogeneric Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Biogeneric Drugs Sales by Application (2015-2020) (K MT)
Table 38. North America Biogeneric Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Biogeneric Drugs Sales by Country (2015-2020) (K MT)
Table 40. Europe Biogeneric Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Biogeneric Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Biogeneric Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Biogeneric Drugs Sales by Type (2015-2020) (K MT)
Table 44. Europe Biogeneric Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Biogeneric Drugs Sales by Application (2015-2020) (K MT)
Table 46. Europe Biogeneric Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Biogeneric Drugs Sales by Region (2015-2020) (K MT)
Table 48. Asia Pacific Biogeneric Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Biogeneric Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Biogeneric Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Biogeneric Drugs Sales by Type (2015-2020) (K MT)
Table 52. Asia Pacific Biogeneric Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Biogeneric Drugs Sales by Application (2015-2020) (K MT)
Table 54. Asia Pacific Biogeneric Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Biogeneric Drugs Sales by Country (2015-2020) (K MT)
Table 56. Latin America Biogeneric Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Biogeneric Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Biogeneric Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Biogeneric Drugs Sales by Type (2015-2020) (K MT)
Table 60. Latin America Biogeneric Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Biogeneric Drugs Sales by Application (2015-2020) (K MT)
Table 62. Latin America Biogeneric Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Biogeneric Drugs Sales by Country (2015-2020) (K MT)
Table 64. Middle East and Africa Biogeneric Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Biogeneric Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Biogeneric Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Biogeneric Drugs Sales by Type (2015-2020) (K MT)
Table 68. Middle East and Africa Biogeneric Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Biogeneric Drugs Sales by Application (2015-2020) (K MT)
Table 70. Middle East and Africa Biogeneric Drugs Sales Market Share by Application (2015-2020)
Table 71. Sandoz International Corporation Information
Table 72. Sandoz International Description and Major Businesses
Table 73. Sandoz International Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 74. Sandoz International Product
Table 75. Sandoz International Recent Development
Table 76. Teva pharmaceutical industries Corporation Information
Table 77. Teva pharmaceutical industries Description and Major Businesses
Table 78. Teva pharmaceutical industries Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 79. Teva pharmaceutical industries Product
Table 80. Teva pharmaceutical industries Recent Development
Table 81. Mylan Corporation Information
Table 82. Mylan Description and Major Businesses
Table 83. Mylan Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. Mylan Product
Table 85. Mylan Recent Development
Table 86. 3SBio Corporation Information
Table 87. 3SBio Description and Major Businesses
Table 88. 3SBio Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. 3SBio Product
Table 90. 3SBio Recent Development
Table 91. Shanghai Fosun Pharmaceutical Corporation Information
Table 92. Shanghai Fosun Pharmaceutical Description and Major Businesses
Table 93. Shanghai Fosun Pharmaceutical Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Shanghai Fosun Pharmaceutical Product
Table 95. Shanghai Fosun Pharmaceutical Recent Development
Table 96. Tonghua Dongbao Pharmaceutical Corporation Information
Table 97. Tonghua Dongbao Pharmaceutical Description and Major Businesses
Table 98. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. Tonghua Dongbao Pharmaceutical Product
Table 100. Tonghua Dongbao Pharmaceutical Recent Development
Table 101. Biocon Corporation Information
Table 102. Biocon Description and Major Businesses
Table 103. Biocon Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 104. Biocon Product
Table 105. Biocon Recent Development
Table 106. Reliance life sciences Corporation Information
Table 107. Reliance life sciences Description and Major Businesses
Table 108. Reliance life sciences Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 109. Reliance life sciences Product
Table 110. Reliance life sciences Recent Development
Table 111. Probiomed Corporation Information
Table 112. Probiomed Description and Major Businesses
Table 113. Probiomed Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 114. Probiomed Product
Table 115. Probiomed Recent Development
Table 116. Biosidus Corporation Information
Table 117. Biosidus Description and Major Businesses
Table 118. Biosidus Biogeneric Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 119. Biosidus Product
Table 120. Biosidus Recent Development
Table 121. AMEGA Biotech Corporation Information
Table 122. AMEGA Biotech Description and Major Businesses
Table 123. AMEGA Biotech Biogeneric Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 124. AMEGA Biotech Product
Table 125. AMEGA Biotech Recent Development
Table 126. Celltrion Corporation Information
Table 127. Celltrion Description and Major Businesses
Table 128. Celltrion Biogeneric Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 129. Celltrion Product
Table 130. Celltrion Recent Development
Table 131. LG life Science Corporation Information
Table 132. LG life Science Description and Major Businesses
Table 133. LG life Science Biogeneric Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 134. LG life Science Product
Table 135. LG life Science Recent Development
Table 136. Dong-A Pharmaceutical Corporation Information
Table 137. Dong-A Pharmaceutical Description and Major Businesses
Table 138. Dong-A Pharmaceutical Biogeneric Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 139. Dong-A Pharmaceutical Product
Table 140. Dong-A Pharmaceutical Recent Development
Table 141. Global Biogeneric Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 142. Global Biogeneric Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 143. Global Biogeneric Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 144. Global Biogeneric Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 145. North America: Biogeneric Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 146. North America: Biogeneric Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 147. Europe: Biogeneric Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 148. Europe: Biogeneric Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Asia Pacific: Biogeneric Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 150. Asia Pacific: Biogeneric Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 151. Latin America: Biogeneric Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 152. Latin America: Biogeneric Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 153. Middle East and Africa: Biogeneric Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 154. Middle East and Africa: Biogeneric Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 155. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 156. Key Challenges
Table 157. Market Risks
Table 158. Main Points Interviewed from Key Biogeneric Drugs Players
Table 159. Biogeneric Drugs Customers List
Table 160. Biogeneric Drugs Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Biogeneric Drugs Product Picture
Figure 2. Global Biogeneric Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Insulins Product Picture
Figure 4. Growth Hormones Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Biogeneric Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinics
Figure 10. Research Centers
Figure 11. Biogeneric Drugs Report Years Considered
Figure 12. Global Biogeneric Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Biogeneric Drugs Sales 2015-2026 (K MT)
Figure 14. Global Biogeneric Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Biogeneric Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Biogeneric Drugs Sales Market Share by Region in 2019
Figure 17. Global Biogeneric Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Biogeneric Drugs Revenue Market Share by Region in 2019
Figure 19. Global Biogeneric Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Biogeneric Drugs Revenue in 2019
Figure 21. Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Biogeneric Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Biogeneric Drugs Sales Market Share by Type in 2019
Figure 24. Global Biogeneric Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Biogeneric Drugs Revenue Market Share by Type in 2019
Figure 26. Global Biogeneric Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Biogeneric Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Biogeneric Drugs Sales Market Share by Application in 2019
Figure 29. Global Biogeneric Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Biogeneric Drugs Revenue Market Share by Application in 2019
Figure 31. North America Biogeneric Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 32. North America Biogeneric Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Biogeneric Drugs Sales Market Share by Country in 2019
Figure 34. North America Biogeneric Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. U.S. Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 38. Canada Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Biogeneric Drugs Market Share by Type in 2019
Figure 40. North America Biogeneric Drugs Market Share by Application in 2019
Figure 41. Europe Biogeneric Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 42. Europe Biogeneric Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Biogeneric Drugs Sales Market Share by Country in 2019
Figure 44. Europe Biogeneric Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. Germany Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. France Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. U.K. Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Italy Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 54. Russia Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Biogeneric Drugs Market Share by Type in 2019
Figure 56. Europe Biogeneric Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Biogeneric Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 58. Asia Pacific Biogeneric Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Biogeneric Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Biogeneric Drugs Revenue Market Share by Region in 2019
Figure 61. China Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. China Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. Japan Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. South Korea Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. India Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Australia Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Taiwan Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Indonesia Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Thailand Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Malaysia Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Philippines Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 82. Vietnam Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Biogeneric Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Biogeneric Drugs Market Share by Application in 2019
Figure 85. Latin America Biogeneric Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 86. Latin America Biogeneric Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Biogeneric Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Biogeneric Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Mexico Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Brazil Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 94. Argentina Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Biogeneric Drugs Market Share by Type in 2019
Figure 96. Latin America Biogeneric Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Biogeneric Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 98. Middle East and Africa Biogeneric Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Biogeneric Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Biogeneric Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Turkey Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. Saudi Arabia Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Biogeneric Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 106. U.A.E Biogeneric Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Biogeneric Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Biogeneric Drugs Market Share by Application in 2019
Figure 109. North America Biogeneric Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. North America Biogeneric Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Biogeneric Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Europe Biogeneric Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Biogeneric Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Asia Pacific Biogeneric Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Biogeneric Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Latin America Biogeneric Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Biogeneric Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. Middle East and Africa Biogeneric Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
バイオエンジニアリングタンパク質医薬品の世界市場（～2026年） Market Analysis and Insights: Global Bioengineered Proteins Drugs Market The global Bioengineered Proteins Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Bioengineered Proteins Drugs Scope and Market Size Bioeng…- 免疫療法薬の世界市場（～2026年） Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. North America is expected to account for largest share in the …
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…
- チロシンヒドロキシラーゼ欠損症治療薬の世界市場（～2026年） The Tyrosine Hydroxylase Deficiency is also known as recessive dopa-responsive dystonia and is a rare genetic disorder. In the Tyrosine Hydroxylase Deficiency, there is lack of enzymes which are involved in converting amino acid tyrosine to L-dopa. A wide range of symptoms can be associated with the…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…